Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Samira Khalili et al.|PLoS ONE|2017Cited by 145
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, Jiong Lan et al.|Clinical Cancer Research|2014Cited by 111
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseasesNeha Dixit, Jonathan Zalevsky, Christie Fanton et al.|Journal of Translational Autoimmunity|2021Cited by 54
Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214Saul Kivimäe, Jonathan Zalevsky, Marlene Hennessy et al.|Cancer Research|2018Cited by 19
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockadeJohn L. Langowski, Deborah H. Charych, Rhoneil Pena et al.|Cancer Research|2016Cited by 2